🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 22 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 22/01/2007 | 36,98 | 37,00 | 35,90 | 35,95 | -2,57% | 2,97% | 1.996.100 |
| 19/01/2007 | 37,38 | 37,80 | 36,84 | 36,90 | -1,13% | 2,57% | 1.846.100 |
| 18/01/2007 | 38,03 | 38,42 | 37,19 | 37,32 | -1,50% | 3,23% | 1.343.100 |
| 17/01/2007 | 38,12 | 38,70 | 37,60 | 37,89 | -1,38% | 2,89% | 2.062.100 |
| 16/01/2007 | 38,50 | 38,95 | 37,82 | 38,42 | +1,64% | 2,94% | 2.883.200 |
| 12/01/2007 | 36,00 | 38,34 | 36,00 | 37,80 | +4,85% | 6,50% | 2.705.000 |
| 11/01/2007 | 35,50 | 36,20 | 35,35 | 36,05 | +1,92% | 2,39% | 1.542.100 |
| 10/01/2007 | 33,63 | 35,58 | 33,55 | 35,37 | +4,43% | 6,04% | 2.366.300 |
| 09/01/2007 | 33,87 | 35,09 | 33,66 | 33,87 | +0,95% | 4,22% | 4.322.400 |
| 08/01/2007 | 36,00 | 36,00 | 33,41 | 33,55 | -6,31% | 7,19% | 4.602.600 |
| 05/01/2007 | 37,02 | 37,06 | 35,78 | 35,81 | -3,19% | 3,46% | 1.548.900 |
| 04/01/2007 | 36,91 | 37,38 | 36,17 | 36,99 | +0,24% | 3,28% | 1.818.600 |
| 03/01/2007 | 37,78 | 38,25 | 36,00 | 36,90 | -1,39% | 5,96% | 1.801.000 |
| 29/12/2006 | 37,70 | 37,80 | 37,22 | 37,42 | -1,16% | 1,54% | 802.300 |
| 28/12/2006 | 37,39 | 38,24 | 37,17 | 37,86 | +1,26% | 2,86% | 949.400 |
| 27/12/2006 | 37,44 | 37,93 | 37,29 | 37,39 | +0,56% | 1,71% | 885.400 |
| 26/12/2006 | 37,33 | 37,58 | 37,00 | 37,18 | -0,88% | 1,55% | 592.600 |
| 22/12/2006 | 37,51 | 38,27 | 37,29 | 37,51 | -0,16% | 2,61% | 1.256.500 |
| 21/12/2006 | 37,88 | 38,39 | 37,31 | 37,57 | +0,32% | 2,85% | 1.551.900 |
| 20/12/2006 | 37,89 | 38,09 | 37,29 | 37,45 | -1,42% | 2,11% | 977.900 |
| 19/12/2006 | 38,36 | 38,43 | 37,38 | 37,99 | -1,48% | 2,74% | 1.192.100 |
| 18/12/2006 | 38,63 | 39,24 | 38,35 | 38,56 | -0,95% | 2,30% | 2.105.200 |
| 15/12/2006 | 38,89 | 39,48 | 38,42 | 38,93 | +0,57% | 2,73% | 4.742.800 |
| 14/12/2006 | 37,81 | 39,06 | 37,81 | 38,71 | +0,03% | 3,31% | 3.174.300 |
| 13/12/2006 | 36,34 | 39,65 | 36,29 | 38,70 | -1,78% | 9,25% | 7.976.000 |
| 12/12/2006 | 41,20 | 41,45 | 39,09 | 39,40 | -4,23% | 5,73% | 2.989.100 |
| 11/12/2006 | 43,59 | 43,60 | 39,49 | 41,14 | -4,83% | 9,43% | 5.626.400 |
| 08/12/2006 | 43,57 | 43,57 | 42,30 | 43,23 | -0,83% | 2,91% | 2.465.300 |
| 07/12/2006 | 44,41 | 44,67 | 43,27 | 43,59 | -2,00% | 3,15% | 2.052.200 |
| 06/12/2006 | 44,73 | 44,98 | 44,20 | 44,48 | -0,13% | 1,74% | 919.000 |